Cargando…

Resting heart rate in ambulatory heart failure with reduced ejection fraction treated with beta‐blockers

AIMS: Current guidelines recommend beta‐blocker therapy in chronic heart failure with reduced ejection fraction (HFrEF) titrated according to tolerated target dose. The efficiency of this strategy to obtain adequate heart rate (HR) control remains unclear in clinical practice. The aim of this study...

Descripción completa

Detalles Bibliográficos
Autores principales:	Varian, Kenneth D., Ji, Xinge, Grodin, Justin L., Verbrugge, Frederik H., Milinovich, Alex, Kattan, Michael W., Tang, W.H. Wilson
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2020
Materias:	Original Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7524238/ https://www.ncbi.nlm.nih.gov/pubmed/32757485 http://dx.doi.org/10.1002/ehf2.12931

Ejemplares similares

Plasma renin activity in patients with heart failure and reduced ejection fraction on optimal medical therapy
por: Nijst, Petra, et al.
Publicado: (2017)

Effects of Beta-Blockers on Heart Failure with Preserved Ejection Fraction: A Meta-Analysis
por: Liu, Feng, et al.
Publicado: (2014)

Investigating the effects of beta-blockers on circadian heart rhythm using heart rate variability in ischemic heart disease with preserved ejection fraction
por: Saleem, Shiza, et al.
Publicado: (2023)

Ultrafiltration in Acute Heart Failure: Implications of Ejection Fraction and Early Response to Treatment From CARRESS‐HF
por: Fudim, Marat, et al.
Publicado: (2020)

Beta-blocker use and cardiovascular event risk in patients with heart failure with preserved ejection fraction
por: Tsujimoto, Tetsuro, et al.
Publicado: (2018)

The progress and controversial of the use of beta blockers in patients with heart failure with a preserved ejection fraction
por: Xu, Xizhen, et al.
Publicado: (2019)

The Use of β-Blockers in Heart Failure with Reduced Ejection Fraction
por: Masarone, Daniele, et al.
Publicado: (2021)

Myocardial strain to identify benefit from beta‐blockers in patients with heart failure with reduced ejection fraction
por: Park, Chan Soon, et al.
Publicado: (2022)

Using Atlanta Heart Failure Questionnaire in ambulatory heart failure patients with preserved ejection fraction HFPEF
por: Alghalayini, Kamal W
Publicado: (2020)

Exercise Systolic Reserve and Exercise Pulmonary Hypertension Improve Diagnosis of Heart Failure With Preserved Ejection Fraction
por: Verwerft, Jan, et al.
Publicado: (2022)

Aggressive beta-blocker titration in stabilized acute heart failure patients with low left ventricular ejection fraction
por: Waranugraha, Yoga, et al.
Publicado: (2021)

Beta-Blockers in Patients with Heart Failure with Preserved Ejection Fraction: Results from The Korea Acute Heart Failure (KorAHF) Registry
por: Kim, Sung-Hwan, et al.
Publicado: (2018)

Mild aortic valve disease and the diastolic pressure–volume relationship in heart failure with preserved ejection fraction
por: Verbrugge, Frederik H, et al.
Publicado: (2021)

Beta-Blockers in Heart Failure with Preserved Ejection Fraction: Could Their Use Be Vindicated as an Acceptable Option in the Future Treatment Guideline?
por: Cho, Jae Yeong
Publicado: (2019)

Patterns of beta-blocker intensification in ambulatory heart failure patients and short-term association with hospitalization
por: Allen, Larry A, et al.
Publicado: (2012)

Body Mass Index, Natriuretic Peptides, and Risk of Adverse Outcomes in Patients With Heart Failure and Preserved Ejection Fraction: Analysis From the TOPCAT Trial
por: Pandey, Ambarish, et al.
Publicado: (2018)

Adding ivabradine to beta-blockers in chronic heart failure: Do not rest without lowering the resting heart rate sufficiently
por: Oomman, Abraham, et al.
Publicado: (2018)

Genome-Wide Association Study of Beta-Blocker Survival Benefit in Black and White Patients with Heart Failure with Reduced Ejection Fraction
por: Luzum, Jasmine A., et al.
Publicado: (2023)

Effects of beta-blocker withdrawal in patients with heart failure with preserved ejection fraction: A protocol for systematic review and meta-analysis
por: Fukuta, Hidekatsu, et al.
Publicado: (2023)

Beta-blocker management in patients admitted for acute heart failure and reduced ejection fraction: a review and expert consensus opinion
por: Schurtz, Guillaume, et al.
Publicado: (2023)

Implications of renin‐angiotensin‐system blocker discontinuation in acute decompensated heart failure with systolic dysfunction
por: Darden, Douglas, et al.
Publicado: (2019)

Management of low blood pressure in ambulatory heart failure with reduced ejection fraction patients
por: Cautela, Jennifer, et al.
Publicado: (2020)

Higher versus lower doses of ACE inhibitors, angiotensin-2 receptor blockers and beta-blockers in heart failure with reduced ejection fraction: Systematic review and meta-analysis
por: Turgeon, Ricky D., et al.
Publicado: (2019)

Beta Blockers Up-Titration in Patients with Heart Failure Reduced Ejection Fraction and Cardiac Resynchronization Therapy, a Single Center Study
por: Masarone, Daniele, et al.
Publicado: (2019)

Identification of Patients with Preclinical Heart Failure with preserved Ejection Fraction Using the H(2)FPEF Score
por: Koepp, Katlyn E., et al.
Publicado: (2022)

Heart failure with preserved ejection fraction
por: ElGuindy, Ahmed, et al.
Publicado: (2012)

β‐Blockers and 1‐Year Postdischarge Mortality for Heart Failure and Reduced Ejection Fraction and Slow Discharge Heart Rate
por: Park, Jin Joo, et al.
Publicado: (2019)

Benefits of β blockers in patients with heart failure and reduced ejection fraction: network meta-analysis
por: Chatterjee, Saurav, et al.
Publicado: (2013)

Benefits of β blockers in patients with heart failure and reduced ejection fraction: network meta-analysis
Publicado: (2013)

Evidence-based beta blocker use associated with lower heart failure readmission and mortality, but not all-cause readmission, among Medicare beneficiaries hospitalized for heart failure with reduced ejection fraction
por: Loop, Matthew Shane, et al.
Publicado: (2020)

Identifying a low‐flow phenotype in heart failure with preserved ejection fraction: a secondary analysis of the RELAX trial
por: Patel, Kershaw V., et al.
Publicado: (2019)

Clinical tolerability of generic versus brand beta blockers in heart failure with reduced left ventricular ejection fraction: a retrospective cohort from heart failure clinic
por: Chanchai, Rattanachai, et al.
Publicado: (2018)

Heart failure with mildly reduced ejection fraction: retrospective study of ejection fraction trajectory risk
por: Miller, Robert J.H., et al.
Publicado: (2022)

Left atrial ejection fraction and outcomes in heart failure with preserved ejection fraction
por: Kanagala, Prathap, et al.
Publicado: (2019)

Prognostic significance of changes in heart rate following uptitration of beta-blockers in patients with sub-optimally treated heart failure with reduced ejection fraction in sinus rhythm versus atrial fibrillation
por: Mordi, Ify R., et al.
Publicado: (2019)

Resting and exercise haemodynamic characteristics of patients with advanced heart failure and preserved ejection fraction
por: Deis, T., et al.
Publicado: (2021)

Thymosin Beta‐4 Is Elevated in Women With Heart Failure With Preserved Ejection Fraction
por: Drum, Chester L., et al.
Publicado: (2017)

Biomarkers in heart failure with preserved ejection fraction
por: Meijers, W. C., et al.
Publicado: (2016)

Heart failure with preserved ejection fraction
por: Rigolli, Marzia, et al.
Publicado: (2013)

Association between the beta‐blockers, calcium channel blockers, all‐cause mortality and length of hospitalization in patients with heart failure with preserved ejection fraction: A meta‐analysis of randomized controlled trials
por: Wu, Mingming, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_k7f2gqica18vfltl32o5t46ajr